{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-24-009345","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.539384+00:00","generated_at":"2026-06-01T23:17:25.271515+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Alzamend Neuro furnishes updated investor presentation for May 2024; no specific new disclosures provided","bullets":["Filed under Item 7.01 as a Regulation FD disclosure; presentation furnished as Exhibit 99.1.","Presentation covers therapeutic drugs for Alzheimer's and other neurodegenerative/psychiatric disorders.","No financial data, clinical trial results, or milestones explicitly stated in the filing's exhibit text.","Company uses the presentation in meetings with investors, stockholders, and analysts.","Filing emphasizes forward-looking statements and risks; no material operational changes announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-24-009345","json":"https://secwatch.observer/filing/0001214659-24-009345.json","markdown":"https://secwatch.observer/filing/0001214659-24-009345.md","text":"https://secwatch.observer/filing/0001214659-24-009345.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924009345/0001214659-24-009345-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465924009345/g5152428k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:17:25.271515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}